Cargando…
Bullous pemphigoid—What do we know about the most recent therapies?
INTRODUCTION: Bullous pemphigoid (BP) is the most common subtype of autoimmune blistering diseases that primarily affects the elderly and is classically defined by the presence of IgG and/or complement C3 against the BP180 and BP230 hemidesmosome proteins. However, most recent studies have introduce...
Autores principales: | Zeng, Faith A. P., Murrell, Dedee F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669062/ https://www.ncbi.nlm.nih.gov/pubmed/36405625 http://dx.doi.org/10.3389/fmed.2022.1057096 |
Ejemplares similares
-
Advances in understanding and managing bullous pemphigoid
por: Zhao, Cathy Y., et al.
Publicado: (2015) -
The efficacy of adding oral sodium cromoglycate to stable treatment for controlling bullous pemphigoid-related pruritus: A retrospective study
por: Keller Rosenthal, Noy, et al.
Publicado: (2022) -
Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review
por: Zeng, Faith A.P., et al.
Publicado: (2022) -
A Systematic Review of Drug-associated Bullous Pemphigoid
por: VERHEYDEN, Matthew J., et al.
Publicado: (2020) -
Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report()()()
por: Bilgic-Temel, Aslı, et al.
Publicado: (2019)